The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study.
Thomas A. Gardner
Consultant or Advisory Role - Dendreon; Dendreon (U); Dendreon (U)
Honoraria - Dendreon; Dendreon; Dendreon
Research Funding - Dendreon; Dendreon; Dendreon
Daniel Peter Petrylak
Consultant or Advisory Role - Dendreon
Research Funding - Dendreon
John M. Corman
Research Funding - Dendreon; Sipuleucel T trials
Simon Hall
Consultant or Advisory Role - Dendreon
Ralph Weinstein
No relevant relationships to disclose
Robert Keyser
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Amanda Sanders
Employment or Leadership Position - Dendreon; Dendreon
Stock Ownership - Dendreon; Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Celestia S. Higano
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon
Other Remuneration - Dendreon